Erratum: Steroid sex hormones, sex hormone binding globulin, and diabetes incidence in the diabetes prevention program (The Journal of Clinical Endocrinology & Metabolism (2015) 100:10 (3778-3786) DOI: 10.1210/jc.2015-2328);Steroid sex hormones, sex hormone-binding globulin, and diabetes incidence in the diabetes prevention program

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 10, 2015, Pages 3778-3786

  Mather, K J ^a   Kim, C ^b   Christophi, C A ^c   Aroda, V R ^d   Knowler, W C ^e   Edelstein, S E ^c   Florez, J C ^a,f,g   Labrie, F ^h   Kahn, S E ⁱ   Goldberg, R B ^j   Barrett Connor, E ^k  

^a BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

^d MEDSTAR RESEARCH INSTITUTE   (United States)

^e NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

^h Endoceutics Inc   (Canada)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

^j UNIVERSITY OF MIAMI   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANOLONE; ESTRADIOL; ESTRONE; ESTRONE SULFATE; GLUCOSE; METFORMIN; PLACEBO; PRASTERONE; PRASTERONE SULFATE; SEX HORMONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; ANDROGEN; ESTROGEN; GLUCOSE BLOOD LEVEL;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETES PREVENTION PROGRAM; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; GLUCOSE BLOOD LEVEL; HEALTH PROGRAM; HUMAN; INCIDENCE; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATHOGENESIS; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; WAIST CIRCUMFERENCE; AGED; ANALYSIS; BLOOD; BODY MASS; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; GENETICS; METABOLISM; MIDDLE AGED; UNITED STATES;

ADULT; AGED; ANDROGENS; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; ESTROGENS; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; SEX HORMONE-BINDING GLOBULIN; UNITED STATES; WAIST CIRCUMFERENCE;

EID: 84943742761     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-3911     Document Type: Erratum

References (35)

1. Ding EL, Song Y, Malik VS, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes:Asystematic review and metaanalysis. JAMA. 2006;295(11):1288-1299.
2. Selvin E, Feinleib M, Zhang L, et al. Androgens and diabetes in men: Results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care. 2007;30(2):234-238.
3. Lakshman KM, Bhasin S, Araujo AB. Sex hormone-binding globulin as an independent predictor of incident type 2 diabetes mellitus in men. J Gerontol A Biol Sci Med Sci. 2010;65(5):503-509.
4. Atlantis E, Lange K, Martin S, et al. Testosterone and modifiable risk factors associated with diabetes in men. Maturitas. 2011;68(3): 279-285.
5. Schipf S, Haring R, Friedrich N, et al. Low total testosterone is associated with increased risk of incident type 2 diabetes mellitus in men: Results from the Study of Health in Pomerania (SHIP). Aging Male. 2011;14(3):168-175.
6. Goto A, Morita A, Goto M, et al. Associations of sex hormonebinding globulin and testosterone with diabetes among men and women (the Saku Diabetes study): A case control study. Cardiovasc Diabetol. 2012;11:130.
7. Ding EL, Song Y, Manson JE, et al. Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N Engl J Med. 2009;361(12):1152-1163.
8. Chen BH, Brennan K, Goto A, et al. Sex hormone-binding globulin and risk of clinical diabetes in American black, Hispanic, and Asian/Pacific Islander postmenopausal women. Clin Chem. 2012;58(10): 1457-1466.
9. Perry JR, Weedon MN, Langenberg C, et al. Genetic evidence that raised sex hormone binding globulin (SHBG) levels reduce the risk of type 2 diabetes. Hum Mol Genet. 2010;19(3):535-544.
10. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403.
11. Diabetes Prevention Program Research Group. HbA1c as a predictor of diabetes and as an outcome in the diabetes prevention program: Arandomized clinical trial. Diabetes care. 2015;38(1):51-58.
12. Ke Y, Bertin J, Gonthier R, Simard JN, Labrie F. A sensitive, simple and robust LC-MS/MS method for the simultaneous quantification of seven androgen-and estrogen-related steroids in postmenopausal serum. J Steroid Biochem Mol Biol. 2014;144(Pt B):523-534.
13. McCaffery JM, Jablonski KA, Franks PW, et al. TCF7L2 polymorphism, weight loss and proinsulin:insulin ratio in the diabetes prevention program. PloS One. 2011;6(7):e21518.
14. Florez JC, Jablonski KA, Bayley N, et al. TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med. 2006;355(3):241-250.
15. Power SG, Bocchinfuso WP, Pallesen M, Warmels-Rodenhiser S, Van Baelen H, Hammond GL. Molecular analyses of a human sex hormone-binding globulin variant: Evidence for an additional carbohydrate chain. J Clin Endocrinol Metab. 1992;75(4):1066-1070.
16. Hardy DO, Cariño C, Catterall JF, Larrea F. Molecular characterization of a genetic variant of the steroid hormone-binding globulin gene in heterozygous subjects. J Clin Endocrinol Metab. 1995;80(4): 1253-1256.
17. Xita N, Tsatsoulis A. Genetic variants of sex hormone-binding globulin and their biological consequences. Mol Cell Endocrinol. 2010; 316(1):60-65.
18. Kitabchi AE, Temprosa M, Knowler WC, et al. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: Effects of lifestyle intervention and metformin. Diabetes. 2005;54(8):2404-2414.
19. Brand JS, Wareham NJ, Dowsett M, et al. Associations of endogenous testosterone andSHBGwith glycated haemoglobin in middleaged and older men. Clin Endocrinol. 2011;74(5):572-578.
20. Colangelo LA,OuyangP, Liu K, et al. Association of endogenous sex hormones with diabetes and impaired fasting glucose in men: Multiethnic study of atherosclerosis. Diabetes Care. 2009;32(6):1049-1051.
21. Laaksonen DE, Niskanen L, Punnonen K, et al. Sex hormones, inflammation and the metabolic syndrome:Apopulation-based study. Eur J Endocrinol. 2003;149(6):601-608.
22. Goodman-Gruen D, Barrett-Connor E. Sex hormone-binding globulin and glucose tolerance in postmenopausal women. The Rancho Bernardo Study. Diabetes Care. 1997;20(4):645-649.
23. Haffner SM, Dunn JF, Katz MS. Relationship of sex hormone-binding globulin to lipid, lipoprotein, glucose, and insulin concentrations in postmenopausal women. Metabolism. 1992;41(3):278-284.
24. Cao J, Li J, Hao W, et al. Correlation of sex hormone and androgen receptor with diabetes mellitus in elderly men. Aging Male. 2011; 14(3):162-167.
25. Krentz AJ, von Mühlen D, Barrett-Connor E. Adipocytokines, sex hormones, and cardiovascular risk factors in postmenopausal women: Factor analysis of the Rancho Bernardo study. Horm Metab Res. 2009;41(10):773-777.
26. Kalyani RR, Franco M, Dobs AS, et al. The association of endogenous sex hormones, adiposity, and insulin resistance with incident diabetes in postmenopausal women. J Clin Endocrinol Metab. 2009;94(11):4127-4135.
27. van Genugten RE, UtzschneiderKM,Tong J, et al. Effects of sex and hormone replacement therapy use on the prevalence of isolated impaired fasting glucose and isolated impaired glucose tolerance in subjects with a family history of type 2 diabetes. Diabetes. 2006; 55(12):3529-3535.
28. Mather KJ, Funahashi T, Matsuzawa Y, et al. Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program. Diabetes. 2008;57(4):980-986.
29. Goldberg RB, Temprosa MG, Mather KJ, et al. Lifestyle and metformin interventions have a durable effect to lower CRP and tPA levels in the diabetes prevention program except in those who develop diabetes. Diabetes Care. 2014;37(8):2253-2260.
30. Billings LK, Jablonski KA, Ackerman RJ, et al. The influence of rare genetic variation in SLC30A8 on diabetes incidence and-cell function. J Clin Endocrinol Metab. 2014;99(5):E926-E930.
31. Hivert MF, Jablonski KA, Perreault L, et al. Updated genetic score based on 34 confirmed type 2 diabetes Loci is associated with diabetes incidence and regression to normoglycemia in the diabetes prevention program. Diabetes. 2011;60(4):1340-1348.
32. Zhang J, Huang X, Liao M, et al. Both total testosterone and sex hormone-binding globulin are independent risk factors for metabolic syndrome: Results from Fangchenggang Area Male Health and Examination Survey in China. Diabetes Metab Res Rev. 2013;29(5): 391-397.
33. Stellato RK, Feldman HA, Hamdy O, Horton ES, McKinlay JB. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: Prospective results from the Massachusetts male aging study. Diabetes Care. 2000;23(4):490-494.
34. Lindstedt G, Lundberg PA, Lapidus L, Lundgren H, Bengtsson C, Björntorp P. Low sex-hormone-binding globulin concentration as independent risk factor for development of NIDDM. 12-yr follow-up of population study of women in Gothenburg, Sweden. Diabetes. 1991;40(1):123-128.
35. Bonnet F, Balkau B, Malécot JM, et al. Sex hormone-binding globulin predicts the incidence of hyperglycemia in women: Interactions with adiponectin levels. Eur J Endocrinol. 2009;161(1):81-85.